```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  AUG 05   New pricing for EUROPATFULL and PCTFULL effective
                   August 1, 2003
 NEWS  5  AUG 13   Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS  6  AUG 18   Data available for download as a PDF in RDISCLOSURE
 NEWS  7  AUG 18   Simultaneous left and right truncation added to PASCAL
 NEWS  8  AUG 18   FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                   Truncation
 NEWS  9  AUG 18   Simultaneous left and right truncation added to ANABSTR
 NEWS 10  SEP 22   DIPPR file reloaded
 NEWS 11  SEP 25   INPADOC: Legal Status data to be reloaded
 NEWS 12  SEP 29   DISSABS now available on STN
 NEWS 13  OCT 10   PCTFULL: Two new display fields added

 NEWS EXPRESS  OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:10:25 ON 17 OCT 2003

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.21       0.21

FILE 'MEDLINE' ENTERED AT 14:10:51 ON 17 OCT 2003

FILE 'USPATFULL' ENTERED AT 14:10:51 ON 17 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE 'DGENE' ENTERED AT 14:10:51 ON 17 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 14:10:51 ON 17 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 14:10:51 ON 17 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 14:10:51 ON 17 OCT 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 14:10:51 ON 17 OCT 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'BIOSIS' ENTERED AT 14:10:51 ON 17 OCT 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s pharmaceutical composition
L1 109368 PHARMACEUTICAL COMPOSITION

=> s angiogenesis and inhibit?
L2 77921 ANGIOGENESIS AND INHIBIT?

=> s l2 and l1
L3 5618 L2 AND L1

=> s l3 and mammal
L4 3108 L3 AND MAMMAL

=> s l4 and human
L5 3043 L4 AND HUMAN

=> s angiogenesis () inhibition
L6 2175 ANGIOGENESIS (W) INHIBITION

=> s l6 and l5
L7 157 L6 AND L5

=> d l7 ti abs ibib 1-15

L7 ANSWER 1 OF 157 USPATFULL on STN
TI Compositions and methods for the diagnosis and treatment of disorders involving **angiogenesis**
AB Compositions and methods are disclosed for stimulating or **inhibiting angiogenesis** and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy.

In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:271452 USPATFULL

TITLE: Compositions and methods for the diagnosis and treatment of disorders involving **angiogenesis**

INVENTOR(S): Baker, Kevin P., Darnestown, MD, UNITED STATES
Ferrara, Napoleone, San Francisco, CA, UNITED STATES
Gerber, Hanspeter, San Francisco, CA, UNITED STATES
Gerritsen, Mary E., San Mateo, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Godowski, Paul J., Hillsborough, CA, UNITED STATES
Gurney, Austin L., Belmont, CA, UNITED STATES
Hillan, Kenneth J., San Francisco, CA, UNITED STATES
Marsters, Scot A., San Carlos, CA, UNITED STATES
Pan, James, Etobicoke, CANADA
Stephan, Jean-Philippe F., Millbrae, CA, UNITED STATES
Watanabe, Colin K., Moraga, CA, UNITED STATES
Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
Ye, Weilan, Foster City, CA, UNITED STATES

PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003191059	A1	20031009
APPLICATION INFO.:	US 2002-223082	A1	20020816 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-81056, filed on 20 Feb 2002, PENDING Continuation of Ser. No. WO 2001-US21735, filed on 9 Jul 2001, PENDING Continuation of Ser. No. WO 2001-US19692, filed on 20 Jun 2001, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 392 Drawing Page(s)
LINE COUNT: 9073
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 157 USPATFULL on STN

TI Compositions and methods for the diagnosis and treatment of disorders involving **angiogenesis**

AB Compositions and methods are disclosed for stimulating or **inhibiting angiogenesis** and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy.

In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:265849 USPATFULL
TITLE: Compositions and methods for the diagnosis and treatment of disorders involving **angiogenesis**
INVENTOR(S): Baker, Kevin P., Darnestown, MD, UNITED STATES
Ferrara, Napoleone, San Francisco, CA, UNITED STATES
Gerber, Hanspeter, San Francisco, CA, UNITED STATES

Gerritsen, Mary E., San Mateo, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Godowski, Paul J., Hillsborough, CA, UNITED STATES
Gurney, Austin L., Belmont, CA, UNITED STATES
Hillan, Kenneth J., San Francisco, CA, UNITED STATES
Marsters, Scot A., San Carlos, CA, UNITED STATES
Pan, James, Etobicoke, CANADA
Stephan, Jean-Philippe F., Millbrae, CA, UNITED STATES
Watanabe, Colin K., Moraga, CA, UNITED STATES
Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
Ye, Weilan, Foster City, CA, UNITED STATES

PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186866	A1	20031002
APPLICATION INFO.:	US 2002-223081	A1	20020816 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-81056, filed on 20 Feb 2002, PENDING Continuation of Ser. No. WO 2001-US21735, filed on 9 Jul 2001, PENDING Continuation of Ser. No. WO 2001-US19692, filed on 20 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232887P	20000915 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 392 Drawing Page(s)
LINE COUNT: 9074
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 157 USPATFULL on STN
TI Methods of **inhibiting angiogenesis** with fragments and homologs of troponin subunit I
AB The present invention relates to pharmaceutical compositions comprising therapeutically effective amounts of troponin C, I or T subunits, fragments or homologs for the treatment of diseases or disorders involving abnormal **angiogenesis** and methods of use thereof.

ACCESSION NUMBER: 2003:265847 USPATFULL
TITLE: Methods of **inhibiting angiogenesis** with fragments and homologs of troponin subunit I
INVENTOR(S): Thorn, Richard M., North Easton, MA, UNITED STATES
Lanser, Marc E., Dover, MA, UNITED STATES
Moses, Marsha A., Brookline, MA, UNITED STATES
Wiederschain, Dmitri G., Brighton, MA, UNITED STATES

PATENT ASSIGNEE(S): Boston Life Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186864	A1	20031002
APPLICATION INFO.:	US 2002-176416	A1	20020618 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-442099, filed on 17 Nov 1999, GRANTED, Pat. No. US 6465431 Continuation-in-part of Ser. No. US 1999-268274, filed on 15 Mar 1999, ABANDONED Continuation-in-part of Ser. No. US 1997-961264, filed on 30 Oct 1997, GRANTED, Pat. No. US 6025331 Continuation of Ser. No. US 1996-602941, filed on 16 Feb 1996, GRANTED, Pat. No. US 5837680

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NIXON PEABODY LLP, 101 FEDERAL ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 2439

L7 ANSWER 4 OF 157 USPATFULL on STN
TI Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
AB The present invention is directed to the administration of vascular targeting agents, particularly a tubulin binding agent, for the treatment of ocular neovascularization, ocular tumors, and conditions such as diabetic retinopathy, retinopathy of prematurity, retinoblastoma and macular degeneration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:258478 USPATFULL
TITLE: Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
INVENTOR(S): Sherris, David, Jamaica Plain, MA, UNITED STATES
Wood, Mark, Milton, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003181531	A1	20030925	
APPLICATION INFO.:	US 2003-344886	A1	20030211	(10)
	WO 2002-US22449		20020715	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 95
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1980
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 157 USPATFULL on STN
TI Novel compounds and methods of use thereof
AB This invention relates to novel heteroatom containing compounds and compositions thereof, and their use for the prevention and treatment of disease. The invention also provides for methods of making the compounds. The invention is based on the discovery that certain heteroatom containing compounds, 3-oxoacetamideindolyl compounds, have potent anticancer, cytotoxic, and anti-angiogenic activity.

ACCESSION NUMBER: 2003:258429 USPATFULL
TITLE: Novel compounds and methods of use thereof
INVENTOR(S): Chen, Chiung-Tong, Taipei, TAIWAN, PROVINCE OF CHINA
Chen, Shu-Jen, Taipei, TAIWAN, PROVINCE OF CHINA
Hsu, Ming-Chu, Taipei, TAIWAN, PROVINCE OF CHINA
Hwang, Der-Ren, Taipei, TAIWAN, PROVINCE OF CHINA
Li, Wen-Tai, Taipei, TAIWAN, PROVINCE OF CHINA
Lin, Chu-Chung, Taipei, TAIWAN, PROVINCE OF CHINA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003181482	A1	20030925	
APPLICATION INFO.:	US 2002-310711	A1	20021205	(10)

	NUMBER	DATE

PRIORITY INFORMATION: US 2001-337962P 20011206 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JEFFREY D. HSI, Fish & Richarson P.C., 225 Franklin Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2068

L7 ANSWER 6 OF 157 USPATFULL on STN
TI Antibody methods for selectively **inhibiting** VEGF
AB Disclosed are antibodies that specifically **inhibit** VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively **inhibit angiogenesis** and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:250491 USPATFULL
TITLE: Antibody methods for selectively **inhibiting** VEGF
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Brekken, Rolf A., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175276	A1	20030918
APPLICATION INFO.:	US 2003-373561	A1	20030224 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-561499, filed on 28 Apr 2000, GRANTED, Pat. No. US 6524583

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131432P	19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Shelley P.M. Fussey, Ph.D., WILLIAMS, MORGAN & AMERSON, P.C., 10333 Richmond, Suite 1100, Houston, TX, 77042
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 10547
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 157 USPATFULL on STN
TI Novel isoforms of vascular endothelial cell growth **inhibitor**
AB This invention discloses two new VEGI isoforms named VEGI-.sub.192a and VEGI-.sub.192b consisting of 192 amino acid residues. These isoforms show endothelial cell-specific expression and share a C-terminal 151-residues segment with the previously described VEGI-.sub.174 and VEGI-.sub.251. Methods of using these isoforms of VEGI in diagnosing, screening agonist and antagonist of the isoforms, and treating various **angiogenesis**-related diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:243833 USPATFULL
TITLE: Novel isoforms of vascular endothelial cell growth **inhibitor**

INVENTOR(S): Li, Luyuan, Pittsburgh, PA, UNITED STATES
Pan, Hongguang, Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170242	A1	20030911
APPLICATION INFO.:	US 2002-294249	A1	20021112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-331190P	20011109 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jie Zhou, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 4471
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 157 USPATFULL on STN
TI Endothelial-cell binding peptides for diagnosis and therapy
AB The present invention relates to peptides and their derivatives which bind to endothelial cells and **inhibit** their proliferation in in vitro assays, e.g., also referred to herein as endothelial cell binding peptide (ECBP) or ECBP sequence. These compositions may be combined with a pharmaceutically acceptable excipient or carrier and used to **inhibit angiogenesis** and **angiogenesis**-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:237847 USPATFULL
TITLE: Endothelial-cell binding peptides for diagnosis and therapy
INVENTOR(S): Gyuris, Jeno, Winchester, MA, UNITED STATES
Lamphere, Lou, Newton, MA, UNITED STATES
Morris, Aaron J., Brighton, MA, UNITED STATES
Tsaioun, Katherine, Belmont, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166004	A1	20030904
APPLICATION INFO.:	US 2002-286457	A1	20021101 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-334822P	20011101 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
NUMBER OF CLAIMS: 66
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 3424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 157 USPATFULL on STN
TI Anti-tumor agents
AB A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to

inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for **inhibiting** **angiogenesis** in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:226301 USPATFULL		
TITLE:	Anti-tumor agents		
INVENTOR(S):	Wallner, Barbara, Cohasset, MA, UNITED STATES Miller, Glenn, Merrimac, MA, UNITED STATES		
PATENT ASSIGNEE(S):	Point Therapeutics, Inc., Boston, MA (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158114	A1	20030821
APPLICATION INFO.:	US 2003-384121	A1	20030307 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-578363, filed on 25 May 2000, PENDING		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-135861P	19990525 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	2082		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 157 USPATFULL on STN

TI Synthetic approach to designed chemical structures

AB This invention relates to the chemical design and production of peptides, peptide structure and three dimensional conformation was assessed using NMR, circular dichroisin and pulsed field gradient NMR. In addition, this invention relates to peptides produced by these methods and to methods for using the peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:220211 USPATFULL		
TITLE:	Synthetic approach to designed chemical structures		
INVENTOR(S):	Gray, Beulah H., Ontario, OR, UNITED STATES Haseman, Judith R., Eagan, MN, UNITED STATES Mayo, Kevin, Minnetonka, MN, UNITED STATES Griffioen, Arjan W., Maastricht, NETHERLANDS		
PATENT ASSIGNEE(S):	Regents of the University of Minnesota, Minneapolis, MN (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153502	A1	20030814
APPLICATION INFO.:	US 2002-300083	A1	20021120 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-194296, filed on 15 Oct 1999, GRANTED, Pat. No. US 6486125 A 371 of International Ser. No. WO 1997-US8944, filed on 23 May 1997, PENDING Continuation-in-part of Ser. No. US 1996-671487, filed on 27 Jun 1996, GRANTED, Pat. No. US 5955577 Continuation-in-part of Ser. No. US 1996-653632, filed on 24 May 1996, GRANTED, Pat. No. US 5830860		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN, 55458
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 157 USPATFULL on STN
TI Compositions and methods related to claudin-7
AB This invention provides for methods of modulating **angiogenesis** and/or endothelial cell proliferation. In particular, applications of reducing or **inhibiting angiogenesis**, tumor growth, endothelial proliferation by the administration of compositions containing Claudin-7 and biological equivalents thereof. The invention also relates to compositions and methods for treatment for disorders associated with angiogeneis (e.g., cancer).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:214296 USPATFULL
TITLE: Compositions and methods related to claudin-7
INVENTOR(S): Nacht, Mariana, Belmont, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003148939	A1	20030807
APPLICATION INFO.:	US 2002-68486	A1	20020205 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-US21474, filed on 7 Aug 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-147752P	19990806 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Elizabeth Lassen, Genzyme Corporation, 15 Pleasant Street Connector, Framingham, MA, 01701-9322
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 157 USPATFULL on STN
TI Method and compositions for **inhibiting angiogenesis** and treating cancer with IL-12 and IL-18
AB A composition useful for preventing, or retarding the growth of, tumor cells contains synergistic amounts of Interleukin-12 and Interleukin-18. Similarly, methods for treating or preventing cancer include co-administering synergistic amounts of IL-12 and IL-18. The resulting anti-tumor effect is greater than the additive effect of either cytokine administered alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:213234 USPATFULL
TITLE: Method and compositions for **inhibiting angiogenesis** and treating cancer with IL-12 and IL-18
INVENTOR(S): Trinchieri, Giorgio, Wynnewood, PA, UNITED STATES
Lee, William M.F., Wynnewood, PA, UNITED STATES
Coughlin, Christina M., Philadelphia, PA, UNITED STATES
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, Philadelphia, PA, 07940 (U.S. corporation)

09/461,061

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003147871	A1	20030807
APPLICATION INFO.:	US 2003-353283	A1	20030129 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-963060, filed on 3 Nov 1997, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOWSON AND HOWSON, ONE SPRING HOUSE CORPORATION CENTER, BOX 457, 321 NORRISTOWN ROAD, SPRING HOUSE, PA, 19477
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1316
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 157 USPATFULL on STN
TI Therapeutic peptide-based constructs
AB The present invention relates generally to small peptide-based constructs, including derivatized constructs, and their therapeutic uses. The sequences of these constructs are based on a reverse subsequence derived from Domain II of bactericidal/permeability-increasingprotein (BPI).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:207834 USPATFULL
TITLE: Therapeutic peptide-based constructs
INVENTOR(S): Little, Roger G., II, 34491 SOUTH HIGHWAY ONE, GUALALA, CA, UNITED STATES 94510
Lin, Jong-Jye, 181 FALCON WAY, HERCULES, CA, UNITED STATES 94547
Gikonyo, J.G. Kinyua, 2885 SHASTA ROAD, BERKELEY, CA, UNITED STATES 94708

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144195	A1	20030731
APPLICATION INFO.:	US 2002-209621	A1	20020730 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-789941, filed on 16 Feb 2001, PENDING Continuation of Ser. No. US 2000-602811, filed on 23 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-344219, filed on 25 Jun 1999, GRANTED, Pat. No. US 6515104 Continuation-in-part of Ser. No. US 1999-344827, filed on 25 Jun 1999, GRANTED, Pat. No. US 6423825
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Janet M. McNicholas, Ph.D., McAndrews, Held & Malloy, Ltd., 34th Floor, 500 W. Madison Street, Chicago, IL, 60661
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 2442
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 157 USPATFULL on STN
TI Anti-tumor synergetic composition
AB There are provided the combined use of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4'-methansulfonyl daunorubicin and an anti-neoplastic anti-mitotic compound and/or a platinum derivative in the treatment of tumors, as well as in the prevention or treatment of metastasis or in the treatment of tumors by **inhibition** of **angiogenesis**
.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:190764 USPATFULL			
TITLE:	Anti-tumor synergetic composition			
INVENTOR(S):	Geroni, Cristina, Milan, ITALY Ripamonti, Marina, Milan, ITALY Caruso, Michele, Milan, ITALY Suarato, Antonino, Milan, ITALY			
PATENT ASSIGNEE(S):	Pharmacia & Upjohn, S.p.A., Milan, ITALY (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6593303	B1	20030715	
	WO 2000050033		20000831	
APPLICATION INFO.:	US 2001-926055		20010822	(9)
	WO 2000-EP746		20000131	
	NUMBER		DATE	
PRIORITY INFORMATION:	GB 1999-4386		19990225	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Wilson, James O.			
ASSISTANT EXAMINER:	Lewis, Patrick			
LEGAL REPRESENTATIVE:	MCDonnell Boehnen Hulbert & Berghoff			
NUMBER OF CLAIMS:	41			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)			
LINE COUNT:	332			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 157 USPATFULL on STN

TI Tumor necrosis factor-gamma

AB **Human** TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to **inhibit** cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:187403 USPATFULL			
TITLE:	Tumor necrosis factor-gamma			
INVENTOR(S):	Yu, Guo-Liang, Berkeley, CA, UNITED STATES Ni, Jian, Germantown, MD, UNITED STATES Rosen, Craig A., Laytonsville, MD, UNITED STATES Zhang, Jun, San Diego, CA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003129189	A1	20030710	
APPLICATION INFO.:	US 2002-226294	A1	20020823	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-899059, filed on 6 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2000-559290, filed on 27 Apr 2000, ABANDONED			

Continuation-in-part of Ser. No. US 1999-246129, filed on 8 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-131237, filed on 7 Aug 1998, PENDING Continuation-in-part of Ser. No. US 1998-5020, filed on 9 Jan 1998, ABANDONED Continuation-in-part of Ser. No. US 1995-461246, filed on 5 Jun 1995, ABANDONED Continuation-in-part of Ser. No. WO 1994-US12880, filed on 7 Nov 1994, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-314381P	20010824 (60)
	US 2001-278449P	20010326 (60)
	US 2000-216879P	20000707 (60)
	US 2000-180908P	20000208 (60)
	US 1999-134067P	19990513 (60)
	US 1999-132227P	19990503 (60)
	US 1999-131963P	19990430 (60)
	US 1998-74047P	19980209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 33 Drawing Page(s)
LINE COUNT: 13325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> s N-terminal truncation fragment
L8            9 N-TERMINAL TRUNCATION FRAGMENT

=> d his

     (FILE 'HOME' ENTERED AT 14:10:25 ON 17 OCT 2003)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
     BIOSIS' ENTERED AT 14:10:51 ON 17 OCT 2003
L1        109368 S PHARMACEUTICAL COMPOSITION
L2         77921 S ANGIOGENESIS AND INHIBIT?
L3          5618 S L2 AND L1
L4          3108 S L3 AND MAMMAL
L5          3043 S L4 AND HUMAN
L6          2175 S ANGIOGENESIS () INHIBITION
L7           157 S L6 AND L5
L8             9 S N-TERMINAL TRUNCATION FRAGMENT

=> s l8 and l7
L9             0 L8 AND L7

=> s C-terminal truncation
L10         1322 C-TERMINAL TRUNCATION

=> s l1 and l9
L11            0 L1 AND L9

=> s l1 and l8
L12            6 L1 AND L8

=> s l1 and l10
L13          154 L1 AND L10

=> s l13 and l7
```

```
L14             0 L13 AND L7

=> s l7 and l12
L15             0 L7 AND L12
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY
NEWS 28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:17:50 ON 01 AUG 2003

=> file medline, uspatful, dgene, embase,
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'MEDLINE' ENTERED AT 16:19:19 ON 01 AUG 2003

FILE 'USPATFULL' ENTERED AT 16:19:19 ON 01 AUG 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 16:19:19 ON 01 AUG 2003
COPYRIGHT (C) 2003 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 16:19:19 ON 01 AUG 2003

=> s angiogenesis () inhibit
L1 24 ANGIOGENESIS (W) INHIBIT

=> d l1 ti abs ibib tot

L1 ANSWER 1 OF 24 USPATFULL on STN
TI Nucleic acid molecules encoding endostatin protein and peptide fragments thereof
AB Endostatin compositions capable of inhibiting endothelial cell proliferation, inhibiting angiogenesis and causing tumor regression are described. Specifically, amino acid sequences of endostatin proteins and nucleic acid sequences coding for endostatin proteins are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:166512 USPATFULL		
TITLE:	Nucleic acid molecules encoding endostatin protein and peptide fragments thereof		
INVENTOR(S):	Folkman, M. Judah, Brookline, MA, UNITED STATES O'Reilly, Michael S., Winchester, MA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003114370	A1	20030619
APPLICATION INFO.:	US 2002-42347	A1	20020111 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-315689, filed on 20 May 1999, GRANTED, Pat. No. US 6346510 Division of Ser. No. US 1998-154302, filed on 16 Sep 1998, PENDING Division of Ser. No. US 1996-740168, filed on 22 Oct 1996, GRANTED, Pat. No. US 5854205		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-106343P	19981030 (60)	
	US 1995-5835P	19951023 (60)	
	US 1996-23070P	19960802 (60)	
	US 1996-26263P	19960917 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Houri Khalilian, Ph.D., Kilpatrick Stockton LLP, Suite 2800, 1100 Peachtree Street, Atlanta, GA, 30309-4530		

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2084
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 24 USPATFULL on STN
TI Therapeutic antiangiogenic compositions and methods
AB An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:127180 USPATFULL
TITLE: Therapeutic antiangiogenic compositions and methods
INVENTOR(S): O'Reilly, Michael S., Winchester, MA, UNITED STATES
Folkman, M. Judah, Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087393	A1	20030508
APPLICATION INFO.:	US 2002-232316	A1	20020903 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-174381, filed on 16 Oct 1998, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN S. PRATT, KILPATRICK STOCKTON LLP, 1100 PEACHTREE, SUITE 2800, ATLANTA, GA, 30309
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2024
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 3 OF 24 USPATFULL on STN
TI Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
AB This invention relates to antibodies, or immunologically active fragments thereof, specific for the N-terminal 15 amino acids of a mammalian VE-cadherin and which act as antagonists of VE-cadherin-mediated homophilic interactions between adjacent endothelial cells without adversely affecting normal vasculature. In a preferred embodiment, the antibodies are humanized antibodies directed that react with human VE-cadherin for use in a human. The invention also provides pharmaceutical compositions comprising these antibodies and antibody fragments, methods of preparing the antibodies, and methods of using the antibodies and antibody fragments to inhibit **angiogenesis**, **inhibit** tumor metastasis, or treat cell proliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:287144 USPATFULL
TITLE: Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
INVENTOR(S): Liao, Fang, New York, NY, UNITED STATES
Hicklin, Daniel J., Glen Ridge, NJ, UNITED STATES
Bohlen, Peter, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160003	A1	20021031
APPLICATION INFO.:	US 2002-40128	A1	20020102 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-540967, filed on 31

Mar 2000, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1119
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 24 USPATFULL on STN
TI THERAPEUTIC ANTIANGIOGENCI COMPOSITIONS AND METHODS
AB An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:280542 USPATFULL
TITLE: THERAPEUTIC ANTIANGIOGENCI COMPOSITIONS AND METHODS
INVENTOR(S): O'REILLY, MICHAEL S., WINCHESTER, MA, UNITED STATES
FOLKMAN, M. JUDAH, BROOKLINE, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002155987	A1	20021024
APPLICATION INFO.:	US 1998-154302	A1	19980916 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-740168, filed on 22 Oct 1996, GRANTED, Pat. No. US 5854205

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-5835P	19951023 (60)
	US 1996-23070P	19960802 (60)
	US 1996-26263P	19960917 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN S. PRATT, KILPATRICK STOCKTON LLP, 1100 PEACHTREE, SUITE 2800, ATLANTA, GA, 30309
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2005
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 24 USPATFULL on STN
TI METHODS OF DETECTING ENDOSTATIN PROTEIN
AB An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:235406 USPATFULL
TITLE: METHODS OF DETECTING ENDOSTATIN PROTEIN
INVENTOR(S): O'REILLY, MICHAEL S., WINCHESTER, MA, UNITED STATES
FOLKMAN, M. JUDAH, BROOKLINE, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002127595	A1	20020912
APPLICATION INFO.:	US 1998-174516	A1	19981016 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-740168, filed on 22 Oct 1996, PATENTED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-5835P	19951023 (60)
	US 1996-23070P	19960802 (60)
	US 1996-26263P	19960917 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN S. PRATT, KILPATRICK STOCKTON LLP, 1100 PEACHTREE, SUITE 2800, ATLANTA, GA, 30309
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2019
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 24 USPATFULL on STN
TI ENDOSTATIN PROTEIN AND FRAGMENTS THEREOF
AB An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:228298 USPATFULL
TITLE: ENDOSTATIN PROTEIN AND FRAGMENTS THEREOF
INVENTOR(S): O'REILLY, MICHAEL S., WINCHESTER, MA, UNITED STATES
FOLKMAN, M. JUDAH, BROOKLINE, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002123458	A1	20020905
APPLICATION INFO.:	US 1999-405499	A1	19990923 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-154302, filed on 16 Sep 1998, PENDING Division of Ser. No. US 1996-740168, filed on 22 Oct 1996, PATENTED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-5835P	19951023 (60)
	US 1996-23070P	19960802 (60)
	US 1996-26263P	19960917 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN S. PRATT, KILPATRICK STOCKTON LLP, 1100 PEACHTREE, SUITE 2800, ATLANTA, GA, 30309
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 2023
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 7 OF 24 USPATFULL on STN
TI METHODS FOR EXPRESSING ENDOSTATIN PROTEIN
AB An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:164734 USPATFULL
TITLE: METHODS FOR EXPRESSING ENDOSTATIN PROTEIN
INVENTOR(S): O'REILLY, MICHAEL S., WINCHESTER, MA, UNITED STATES
FOLKMAN, M. JUDAH, BROOKLINE, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002086352	A1	20020704	
	US 6544758	B2	20030408	
APPLICATION INFO.:	US 1998-174282	A1	19981016	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1995-5835P	19951023	(60)
	US 1996-23070P	19960802	(60)
	US 1996-26263P	19960917	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN S. PRATT, KILPATRICK STOCKTON LLP, 1100 PEACHTREE, SUITE 2800, ATLANTA, GA, 30309
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2024
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 8 OF 24 USPATFULL on STN
TI Angiostatin and endostatin binding proteins and methods of use
AB The present invention is related to compositions and methods for the modulation of angiogenesis. In particular, the present invention includes Angiostatin and Endostatin binding peptides and proteins and methods of using the same. The present invention identifies tropomyosin protein as an Endostatin binding protein and a laminin beta-1 chain as an Angiostatin binding protein. The present invention also provides methods of inhibiting angiogenesis in an individual comprising administering to the individual a tropomyosin binding compound and/or an actin cytoskeleton disrupting compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:149133 USPATFULL
TITLE: Angiostatin and endostatin binding proteins and methods of use
INVENTOR(S): MacDonald, Nicholas J., Chevy Chase, MD, UNITED STATES
Sim, Kim L., Gaithersburg, MD, UNITED STATES
Holaday, John W., Bethesda, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002077289	A1	20020620	
APPLICATION INFO.:	US 2001-873676	A1	20010604	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-209065P	20000602	(60)
	US 2001-289387P	20010508	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, SUITE 2800, ATLANTA, GA, 30309
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 2649
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 9 OF 24 USPATFULL on STN
TI Substituted 1-oxo- and 1,3-dioxoisoindoline and method of reducing inflammatory cytokine levels

AB 1-Oxo- and 1,3-dioxoisoindolines substituted in the 4- or 5-position of the indoline ring reduce the levels of inflammatory cytokines such as TNF.alpha. in a mammal. A typical embodiment is 4-(4-amino-1,3-dioxoisoindolin-2-yl)-4-carbamoylbutanoic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:95828 USPATFULL		
TITLE:	Substituted 1-oxo- and 1,3-dioxoisoindoline and method of reducing inflammatory cytokine levels		
INVENTOR(S):	Muller, George W., Bridgewater, NJ, United States Stirling, David, Branchburg, NJ, United States		
PATENT ASSIGNEE(S):	Celgene Corporation, Warren, NJ, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6380239	B1	20020430
APPLICATION INFO.:	US 2000-528785		20000317 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1999-124942P		19990318 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Ramsuer, Robert W.		
ASSISTANT EXAMINER:	Murray, Joseph		
LEGAL REPRESENTATIVE:	Buckwalter, Brian L., Mathews, Collins, Shepherd & McKay, P.A.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	1226		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 10 OF 24 USPATFULL on STN

TI Therapeutic antiangiogenic endostatin compositions

AB Endostatin compositions capable of inhibiting endothelial cell proliferation, inhibiting angiogenesis and causing tumor regression are described. Specifically, amino acid sequences of endostatin proteins and nucleic acid sequences coding for endostatin proteins are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:29365 USPATFULL		
TITLE:	Therapeutic antiangiogenic endostatin compositions		
INVENTOR(S):	O'Reilly, Michael S., Winchester, MA, United States Folkman, M. Judah, Brookline, MA, United States		
PATENT ASSIGNEE(S):	The Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6346510	B1	20020212
APPLICATION INFO.:	US 1999-315689		19990520 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-154302, filed on 16 Sep 1998 Division of Ser. No. US 1996-740168, filed on 22 Oct 1996, now patented, Pat. No. US 5854205		
	NUMBER		DATE
PRIORITY INFORMATION:	US 1998-106343P		19981030 (60)
	US 1995-5835P		19951023 (60)
	US 1996-23070P		19960802 (60)
	US 1996-26263P		19960917 (60)
DOCUMENT TYPE:	Utility		

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Huff, Sheela
LEGAL REPRESENTATIVE: Kilpatrick Stockton LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 11 OF 24 USPATFULL on STN
TI Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
AB The present invention provides methods of inhibiting angiogenesis by increasing the concentration of endostatin protein or endostatin protein fragments in vivo. The methods of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:8028 USPATFULL
TITLE: Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
INVENTOR(S): O'Reilly, Michael S., Winchester, MA, United States
Folkman, M. Judah, Brookline, MA, United States
PATENT ASSIGNEE(S): The Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6174861	B1	20010116
APPLICATION INFO.:	US 1999-349429		19990707 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-154302, filed on 16 Sep 1998 Division of Ser. No. US 1996-740168, filed on 22 Oct 1996, now patented, Pat. No. US 5854205

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-5835P	19951023 (60)
	US 1996-23070P	19960802 (60)
	US 1996-26263P	19960917 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
LEGAL REPRESENTATIVE: Stockton LLP, Kilpatrick
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 12 OF 24 USPATFULL on STN
TI Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
AB Novel and known bicyclic 4-aralkylaminopyrimidine derivatives of formula (I) wherein A is a benzene or imidazole ring; B is a benzene, tetralin, indane or 2-oxindole ring R is (C.sub.1 -C.sub.4)perfluoroalkyl, phenyl, phenyl-(C.sub.1 -C.sub.4)alkyl, hydroxy-(C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy-(C.sub.1 -C.sub.4)alkyl, (C.sub.2 -C.sub.4)acyloxy-(C.sub.1 -C.sub.4)alkyl, halobenzoyloxy-(C.sub.1 -C.sub.4)alkyl, carboxy, carbamoyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, cyano, (C.sub.1 -C.sub.4)alkylcarbonyl, carboxy-(C.sub.1 -C.sub.4)alkyl, carbamoyl-(C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxycarbonyl-(C.sub.1 -C.sub.4)alkyl, halo-(C.sub.1 -C.sub.4)alkyl, amino-(C.sub.1 -C.sub.4)alkyl, mono- or di-(C.sub.1 -C.sub.4)alkylamino-(C.sub.1 -C.sub.4)alkyl, sulfo-(C.sub.1 -C.sub.4)alkyl or sulfamido-(C.sub.1

-C.sub.4)alkyl; each of R.sub.1 and R.sub.2, which may be the same or different, is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen or --NR.sub.5 R.sub.6 in which each of R.sub.5 and R.sub.6, which may be the same or different, is H or C.sub.1 -C.sub.4 alkyl; each of R.sub.3 and R.sub.4, which may the same or different, is hydrogen, C.sub.1 -C.sub.4 alkyl, halogen, hydroxy, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkoxycarbonyl, nitro, cyano or CF.sub.3 ; and the pharmaceutically acceptable salts thereof, are tyrosine kinase inhibitors. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:54109 USPATFULL			
TITLE:	Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors			
INVENTOR(S):	Brasca, Maria Gabriella, Cusago, Italy Ballinari, Dario, San Donato Milanese, Italy Longo, Antonio, Milan, Italy Buzzetti, Franco, Monza, Italy			
PATENT ASSIGNEE(S):	Pharmacia & Upjohn S.p.A, Milan, Italy (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6057326		20000502	
	WO 9749689		19971231	
APPLICATION INFO.:	US 1998-238		19980206	(9)
	WO 1997-EP2965		19970603	
			19980206	PCT 371 date
			19980206	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	GB 1996-13021		19960621	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Raymond, Richard L.			
ASSISTANT EXAMINER:	Liu, Hong			
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1097			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 13 OF 24 USPATFULL on STN

TI Therapeutic antiangiogenic compositions and methods

AB Isolated endostatin protein that is an inhibitor of endothelial cell proliferation and angiogenesis. Endostatin protein has a molecular weight of approximately 18 kDa as determined by non-reducing gel electrophoresis or approximately 20 kDa as determined by reducing gel electrophoresis. Endostatin protein corresponds to a C-terminal fragment of collagen type XVIII, and the protein can be isolated from the murine hemangioendothelioma EOMA cell line.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:162470 USPATFULL			
TITLE:	Therapeutic antiangiogenic compositions and methods			
INVENTOR(S):	O'Reilly, Michael S., Winchester, MA, United States Folkman, M. Judah, Brookline, MA, United States			
PATENT ASSIGNEE(S):	The Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5854205		19981229	

APPLICATION INFO.: US 1996-740168 19961022 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-5835P	19951023 (60)
	US 1996-23070P	19960802 (60)
	US 1996-26263P	19960917 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
ASSISTANT EXAMINER: Eyler, Yvonne
LEGAL REPRESENTATIVE: Jones & Askew
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1,8
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 2270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 14 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
AN AAY81999 peptide DGENE
AB The present sequence is derived from human two-chain high molecular weight kininogen (HKa) domain 5. HKa is product of high molecular weight kininogen (HK) cleavage by plasma kallikrein. HK is a 120 kD glycoprotein which binds with high affinity to endothelial cells. Hka or a synthetic compound comprising the present sequence may be used in a pharmaceutical composition for inhibiting angiogenesis. Angiogenesis occurs in a number of disease states, such as tumour formation and expansion, and certain ocular disorders. It can also occur in a rheumatoid joint, hastening joint destruction by allowing an influx of leukocytes. The composition may inhibit angiogenesis by inhibiting endothelial cell proliferation or by inducing endothelial cell apoptosis. Peptides used in the compostion may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesised, using, for example, solid phase synthesis methods.
ACCESSION NUMBER: AAY81999 peptide DGENE
TITLE: A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
INVENTOR: McCrae R K
PATENT ASSIGNEE: (UTEM)UNIV TEMPLE.
(MCCR-I) MCCRAE R K.
PATENT INFO: WO 2000027866 A1 20000518 52p
APPLICATION INFO: WO 1999-US26419 19991105
PRIORITY INFO: US 1998-107833 19981110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-376483 [32]
DESCRIPTION: Human two-chain high molecular weight kininogen domain 5 fragment #8.

L1 ANSWER 15 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
AN AAY81998 peptide DGENE
AB The present sequence is derived from human two-chain high molecular weight kininogen (HKa) domain 5. HKa is product of high molecular weight kininogen (HK) cleavage by plasma kallikrein. HK is a 120 kD glycoprotein which binds with high affinity to endothelial cells. Hka or a synthetic compound comprising the present sequence may be used in a pharmaceutical composition for inhibiting angiogenesis. Angiogenesis occurs in a number

of disease states, such as tumour formation and expansion, and certain ocular disorders. It can also occur in a rheumatoid joint, hastening joint destruction by allowing an influx of leukocytes. The composition may inhibit angiogenesis by inhibiting endothelial cell proliferation or by inducing endothelial cell apoptosis. Peptides used in the compostion may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesised, using, for example, solid phase synthesis methods.

ACCESSION NUMBER: AAY81998 peptide DGENE
TITLE: A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
INVENTOR: McCrae R K
PATENT ASSIGNEE: (UTEM) UNIV TEMPLE.
(MCCR-I) MCCRAE R K.
PATENT INFO: WO 2000027866 A1 20000518 52p
APPLICATION INFO: WO 1999-US26419 19991105
PRIORITY INFO: US 1998-107833 19981110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-376483 [32]
DESCRIPTION: Human two-chain high molecular weight kininogen domain 5 fragment #7.

L1 ANSWER 16 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
AN AAY81997 peptide DGENE
AB The present sequence is derived from human high molecular weight kininogen (HK) domain 5. HK is a 120 kD glycoprotein which binds with high affinity to endothelial cells, where it is cleaved to two-chain high molecular weight kininogen (HKa) by plasma kallikrein. Hka or a synthetic compound comprising the present sequence may be used in a pharmaceutical composition for inhibiting angiogenesis. Angiogenesis occurs in a number of disease states, such as tumour formation and expansion, and certain ocular disorders. It can also occur in a rheumatoid joint, hastening joint destruction by allowing an influx of leukocytes. The composition may inhibit angiogenesis by inhibiting endothelial cell proliferation or by inducing endothelial cell apoptosis. Peptides used in the compostion may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesised, using, for example, solid phase synthesis methods.

ACCESSION NUMBER: AAY81997 peptide DGENE
TITLE: A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
INVENTOR: McCrae R K
PATENT ASSIGNEE: (UTEM) UNIV TEMPLE.
(MCCR-I) MCCRAE R K.
PATENT INFO: WO 2000027866 A1 20000518 52p
APPLICATION INFO: WO 1999-US26419 19991105
PRIORITY INFO: US 1998-107833 19981110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-376483 [32]
DESCRIPTION: Human high molecular weight kininogen domain 5 fragment #6.

L1 ANSWER 17 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
AN AAY81996 peptide DGENE
AB The present sequence is derived from human high molecular weight

kininogen (HK) domain 5. HK is a 120 kD glycoprotein which binds with high affinity to endothelial cells, where it is cleaved to two-chain high molecular weight kininogen (HKa) by plasma kallikrein. Hka or a synthetic compound comprising the present sequence may be used in a pharmaceutical composition for inhibiting angiogenesis. Angiogenesis occurs in a number of disease states, such as tumour formation and expansion, and certain ocular disorders. It can also occur in a rheumatoid joint, hastening joint destruction by allowing an influx of leukocytes. The composition may inhibit angiogenesis by inhibiting endothelial cell proliferation or by inducing endothelial cell apoptosis. Peptides used in the compostion may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesised, using, for example, solid phase synthesis methods.

ACCESSION NUMBER: AAY81996 peptide DGENE
TITLE: A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
INVENTOR: McCrae R K
PATENT ASSIGNEE: (UTEM)UNIV TEMPLE.
(MCCR-I) MCCRAE R K.
PATENT INFO: WO 2000027866 A1 20000518 . 52p
APPLICATION INFO: WO 1999-US26419 19991105
PRIORITY INFO: US 1998-107833 19981110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-376483 [32]
DESCRIPTION: Human high molecular weight kininogen domain 5 fragment #5.

L1 ANSWER 18 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
AN AAY81995 peptide DGENE
AB The present sequence is derived from human high molecular weight kininogen (HK) domain 5. HK is a 120 kD glycoprotein which binds with high affinity to endothelial cells, where it is cleaved to two-chain high molecular weight kininogen (HKa) by plasma kallikrein. Hka or a synthetic compound comprising part or all of the present sequence may be used in a pharmaceutical composition for inhibiting angiogenesis. Angiogenesis occurs in a number of disease states, such as tumour formation and expansion, and certain ocular disorders. It can also occur in a rheumatoid joint, hastening joint destruction by allowing an influx of leukocytes. The composition may inhibit angiogenesis by inhibiting endothelial cell proliferation or by inducing endothelial cell apoptosis. Peptides used in the compostion may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesised, using, for example, solid phase synthesis methods.

ACCESSION NUMBER: AAY81995 peptide DGENE
TITLE: A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
INVENTOR: McCrae R K
PATENT ASSIGNEE: (UTEM)UNIV TEMPLE.
(MCCR-I) MCCRAE R K.
PATENT INFO: WO 2000027866 A1 20000518 52p
APPLICATION INFO: WO 1999-US26419 19991105
PRIORITY INFO: US 1998-107833 19981110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-376483 [32]
DESCRIPTION: Human high molecular weight kininogen domain 5 fragment #4.

L1 ANSWER 19 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI A pharmaceutical composition used to inhibit **angiogenesis**,

inhibit endothelial cell proliferation, and induce endothelial cell apoptosis -

AN AAY81994 peptide DGENE

AB The present sequence is derived from human high molecular weight kininogen (HK) domain 5. HK is a 120 kD glycoprotein which binds with high affinity to endothelial cells, where it is cleaved to two-chain high molecular weight kininogen (HKa) by plasma kallikrein. Hka or a synthetic compound comprising part or all of the present sequence may be used in a pharmaceutical composition for inhibiting angiogenesis. Angiogenesis occurs in a number of disease states, such as tumour formation and expansion, and certain ocular disorders. It can also occur in a rheumatoid joint, hastening joint destruction by allowing an influx of leukocytes. The composition may inhibit angiogenesis by inhibiting endothelial cell proliferation or by inducing endothelial cell apoptosis. Peptides used in the compostion may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesised, using, for example, solid phase synthesis methods.

ACCESSION NUMBER: AAY81994 peptide DGENE

TITLE: A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -

INVENTOR: McCrae R K

PATENT ASSIGNEE: (UTEM)UNIV TEMPLE.

(MCCR-I) MCCRAE R K.

PATENT INFO: WO 2000027866 A1 20000518 52p

APPLICATION INFO: WO 1999-US26419 19991105

PRIORITY INFO: US 1998-107833 19981110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-376483 [32]

DESCRIPTION: Human high molecular weight kininogen domain 5 fragment #3.

L1 ANSWER 20 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

TI A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -

AN AAY81993 peptide DGENE

AB The present sequence is derived from human high molecular weight kininogen (HK) domain 5. HK is a 120 kD glycoprotein which binds with high affinity to endothelial cells, where it is cleaved to two-chain high molecular weight kininogen (HKa) by plasma kallikrein. Hka or a synthetic compound comprising part or all of the present sequence may be used in a pharmaceutical composition for inhibiting angiogenesis. Angiogenesis occurs in a number of disease states, such as tumour formation and expansion, and certain ocular disorders. It can also occur in a rheumatoid joint, hastening joint destruction by allowing an influx of leukocytes. The composition may inhibit angiogenesis by inhibiting endothelial cell proliferation or by inducing endothelial cell apoptosis. Peptides used in the compostion may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesised, using, for example, solid phase synthesis methods.

ACCESSION NUMBER: AAY81993 peptide DGENE

TITLE: A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -

INVENTOR: McCrae R K

PATENT ASSIGNEE: (UTEM)UNIV TEMPLE.

(MCCR-I) MCCRAE R K.

PATENT INFO: WO 2000027866 A1 20000518 52p

APPLICATION INFO: WO 1999-US26419 19991105

PRIORITY INFO: US 1998-107833 19981110

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-376483 [32]

DESCRIPTION: Human high molecular weight kininogen domain 5 fragment #2.

L1 ANSWER 21 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
AN AAY81992 peptide DGENE
AB The present sequence is derived from human high molecular weight kininogen (HK) domain 5. HK is a 120 kD glycoprotein which binds with high affinity to endothelial cells, where it is cleaved to two-chain high molecular weight kininogen (HKa) by plasma kallikrein. Hka or a synthetic compound comprising part or all of the present sequence may be used in a pharmaceutical composition for inhibiting angiogenesis. Angiogenesis occurs in a number of disease states, such as tumour formation and expansion, and certain ocular disorders. It can also occur in a rheumatoid joint, hastening joint destruction by allowing an influx of leukocytes. The composition may inhibit angiogenesis by inhibiting endothelial cell proliferation or by inducing endothelial cell apoptosis. Peptides used in the compostion may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesised, using, for example, solid phase synthesis methods.
ACCESSION NUMBER: AAY81992 peptide DGENE
TITLE: A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
INVENTOR: McCrae R K
PATENT ASSIGNEE: (UTEM)UNIV TEMPLE.
(MCCR-I) MCCRAE R K.
PATENT INFO: WO 2000027866 A1 20000518 52p
APPLICATION INFO: WO 1999-US26419 19991105
PRIORITY INFO: US 1998-107833 19981110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-376483 [32]
DESCRIPTION: Human high molecular weight kininogen domain 5 fragment #1.

L1 ANSWER 22 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
AN AAB06337 Protein DGENE
AB The present sequence is derived from human two-chain high molecular weight kininogen (HKa) domain 5. HKa is product of high molecular weight kininogen (HK) cleavage by plasma kallikrein. HK is a 120 kD glycoprotein which binds with high affinity to endothelial cells. Hka or a synthetic compound comprising the present sequence may be used in a pharmaceutical composition for inhibiting angiogenesis. Angiogenesis occurs in a number of disease states, such as tumour formation and expansion, and certain ocular disorders. It can also occur in a rheumatoid joint, hastening joint destruction by allowing an influx of leukocytes. The composition may inhibit angiogenesis by inhibiting endothelial cell proliferation or by inducing endothelial cell apoptosis. Peptides used in the compostion may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesised, using, for example, solid phase synthesis methods.
ACCESSION NUMBER: AAB06337 Protein DGENE
TITLE: A pharmaceutical composition used to inhibit **angiogenesis**, **inhibit** endothelial cell proliferation, and induce endothelial cell apoptosis -
INVENTOR: McCrae R K
PATENT ASSIGNEE: (UTEM)UNIV TEMPLE.
(MCCR-I) MCCRAE R K.
PATENT INFO: WO 2000027866 A1 20000518 52p
APPLICATION INFO: WO 1999-US26419 19991105

PRIORITY INFO: US 1998-107833 19981110
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-376483 [32]
DESCRIPTION: Human two-chain high molecular weight kininogen domain 5 fragment #9.

L1 ANSWER 23 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New secreted human proteins - used to inhibit **angiogenesis**, **inhibit** growth or proliferation of vascular endothelial cells and inhibit tumour growth
AN AAW94655 Protein DGENE
AB The present sequence is a human secreted protein from clone AM931. The polynucleotides and proteins from clone AM931 are predicted to have biological activities which would make them suitable for treating, preventing or ameliorating medical conditions in humans and animals. Suggested activities include nutritional activity, cytokine and cell proliferation/differentiation activity, immune stimulating (e.g. as vaccines) or suppressing activity, haematopoiesis regulating activity, tissue growth activity, activin/inhibin activity, chemotactic/ chemokinetic activity, haemostatic and thrombolytic activity, receptor/ligand activity, anti-inflammatory activity, cadherin/tumour invasion suppressor activity, and tumour inhibition activity. The proteins can be administered to a subject to produce inhibition of angiogenesis, inhibition of growth or proliferation of vascular endothelial cells, inhibition of tumour growth or inhibition of angiogenesis-dependent tissue growth. The polynucleotides are also stated to be useful for gene therapy.
ACCESSION NUMBER: AAW94655 Protein DGENE
TITLE: New secreted human proteins - used to inhibit **angiogenesis**, **inhibit** growth or proliferation of vascular endothelial cells and inhibit tumour growth
INVENTOR: Agostino M J; Jacobs K; Lavallie E R; McCoy J M; Merberg D; Racie L A; Spaulding V; Treacy M
PATENT ASSIGNEE: (GEMY)GENETICS INST INC.
PATENT INFO: WO 9900404 A1 19990107 47p
APPLICATION INFO: WO 1998-US13234 19980626
PRIORITY INFO: US 1997-885469 19970627
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-095670 [08]
CROSS REFERENCES: N-PSDB: AAX16674
DESCRIPTION: Human secreted protein clone AM931.

L1 ANSWER 24 OF 24 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI New secreted human proteins - used to inhibit **angiogenesis**, **inhibit** growth or proliferation of vascular endothelial cells and inhibit tumour growth
AN AAX16674 cDNA DGENE
AB The present sequence encodes a human secreted protein from clone AM931. The polynucleotides and proteins from clone AM931 are predicted to have biological activities which would make them suitable for treating, preventing or ameliorating medical conditions in humans and animals. Suggested activities include nutritional activity, cytokine and cell proliferation/differentiation activity, immune stimulating (e.g. as vaccines) or suppressing activity, haematopoiesis regulating activity, tissue growth activity, activin/inhibin activity, chemotactic/ chemokinetic activity, haemostatic and thrombolytic activity, receptor/ligand activity, anti-inflammatory activity, cadherin/tumour invasion suppressor activity, and tumour inhibition activity. The proteins can be administered to a subject to produce inhibition of angiogenesis, inhibition of growth or proliferation of vascular endothelial cells, inhibition of tumour growth or inhibition of

angiogenesis-dependent tissue growth. The polynucleotides are also stated to be useful for gene therapy.

ACCESSION NUMBER: AAX16674 cDNA DGENE
TITLE: New secreted human proteins - used to inhibit **angiogenesis**, **inhibit** growth or proliferation of vascular endothelial cells and inhibit tumour growth
INVENTOR: Agostino M J; Jacobs K; Lavallie E R; McCoy J M; Merberg D; Racie L A; Spaulding V; Treacy M
PATENT ASSIGNEE: (GEMY)GENETICS INST INC.
PATENT INFO: WO 9900404 A1 19990107 47p
APPLICATION INFO: WO 1998-US13234 19980626
PRIORITY INFO: US 1997-885469 19970627
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-095670 [08]
CROSS REFERENCES: P-PSDB: AAW94655
DESCRIPTION: Human secreted protein clone AM931 encoding cDNA.

=> d his

(FILE 'HOME' ENTERED AT 16:17:50 ON 01 AUG 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE' ENTERED AT 16:19:19 ON 01 AUG 2003
L1 24 S ANGIOGENESIS () INHIBIT

=> s composition () peptide
L2 228 COMPOSITION (W) PEPTIDE

=> s l2 and l1
L3 0 L2 AND L1